Wall Street brokerages predict that Clearside Biomedical Inc (NASDAQ:CLSD) will announce ($0.63) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Clearside Biomedical’s earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.72). Clearside Biomedical reported earnings of ($0.72) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.5%. The firm is expected to announce its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Clearside Biomedical will report full year earnings of ($2.49) per share for the current financial year, with EPS estimates ranging from ($2.73) to ($2.04). For the next year, analysts anticipate that the firm will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.35) to ($1.15). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.12).
Shares of CLSD stock opened at $1.98 on Tuesday. The stock has a market cap of $71.09 million, a price-to-earnings ratio of -0.85 and a beta of -3.98. Clearside Biomedical has a 1 year low of $1.90 and a 1 year high of $15.33. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.94 and a current ratio of 7.94.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC purchased a new position in shares of Clearside Biomedical during the second quarter worth about $123,000. BlackRock Inc. grew its holdings in shares of Clearside Biomedical by 53.1% during the second quarter. BlackRock Inc. now owns 1,859,948 shares of the company’s stock worth $19,883,000 after buying an additional 645,292 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Clearside Biomedical during the second quarter worth about $2,138,000. Alps Advisors Inc. purchased a new position in shares of Clearside Biomedical during the second quarter worth about $496,000. Finally, GSA Capital Partners LLP acquired a new stake in Clearside Biomedical in the second quarter valued at about $534,000. 62.23% of the stock is currently owned by hedge funds and other institutional investors.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
See Also: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.